Speakers

Expand/Collapse

Mallika Singh
Vice President, Translational Research
Revolution Medicine

Day One

Wednesday, February 23rd 2022

10:40 am | Live Panel Q&A - Ask the Speakers Your Burning Questions

2:30 pm | Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers

9:00 am | Mutant-Selective Inhibitors of RAS(ON) Beyond KRASG12C

Jack Sadowsky
Principal Investigator of Discovery Chemistry
Carmot Therapeutics

Day Two

Thursday, 24th February 2022

10:40 am | Live Panel Q&A - Ask the Speakers Your Burning Questions

9:50 am | Chemotype Evolution Platform for Discovering Covalent Inhibitors of KRAS G12C & Beyond

Jeffrey Rothman
Assistant Professor
Columbia University Medical Center & CSO, Founder Oncogenuity

Day One

Wednesday, February 23rd 2022

10:40 am | Live Panel Q&A - Ask the Speakers Your Burning Questions

2:30 pm | Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers

9:50 am | Rationale for Complementary Targeting & Peptide Nucleic Acid Oligonucleotide Delivery for Allele-Specific Targeting of KRAS G12D

Iris Valtingojer
Group Leader, Oncology Research
Sanofi R&D

Day One

Wednesday, February 23rd 2022

5:40 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

4:50 pm | MAPK & Hippo-YAP1 Signaling: At the Crossroads of Cancer Progression & Resistance to Therapy

Hanna Budayeva
Principal Scientific Researcher
Genentech

Day Two

Thursday, 24th February 2022

3:15 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

2:00 pm | Increasing the Throughput of Ligandable Cysteine Hotspots Profiling by Mass Spectrometry to Guide RAS Pathway Drug Discovery

Nicholas Goldner
Chief Executive Officer, Co-Founder
ResistanceBio

Sabine Jurado
Associate Principal Scientist
Boehringer Ingelheim RCV GmbH & Co KG

Day One

Wednesday, February 23rd 2022

1:15 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

12:00 pm | How to Study & Overcome KRAS G12i Resistance

Hugh Slater
Chief Scientific Officer
Anocca

Day Two

Thursday, 24th February 2022

10:40 am | Live Panel Q&A - Ask the Speakers Your Burning Questions

9:00 am | T-Cell Receptor Targeting of Multiple RAS Mutant Forms in Broad Patient Populations

Tommy Turbyville
Principal Scientist, RAS Imaging and Assays, RAS Initiative
Frederick National Laboratory for Cancer Research

Armon Sharei
CEO & Founder
SQZ Biotechnologies

Day Two

Thursday, 24th February 2022

10:40 am | Live Panel Q&A - Ask the Speakers Your Burning Questions

9:25 am | 2nd Generation Antigen Presenting Cells for Multiple KRAS Mutations

Carmine Fedele
Principal Scientist II, Oncology-Drug Discovery
Novartis Institute of Biomedical Research

Marcel Frenkel
Chief Executive Officer
Ten63 Therapeutics

Kevin Pong
Vice President, Business Development
Anima Biotech

Day Two

Thursday, 24th February 2022

10:40 am | Live Panel Q&A - Ask the Speakers Your Burning Questions

10:15 am | Anima’s Pan-KRAS mRNA Translation Modulators in mKRAS Driven Tumors

Jeff Ecsedy
Chief Scientific Officer
Ikena Oncology

Day One

Wednesday, February 23rd 2022

1:15 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

2:30 pm | Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers

12:50 pm | Overcoming Therapeutic Resistance by Targeting Mutant-KRAS Transducers

Thomas Tibbitts
Chief Executive Officer
Dogodan Therapeutics

Day Two

Thursday, 24th February 2022

3:15 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

2:25 pm | Developing Genomic Medicines for KRAS-Driven Cancers

Poulikos Poulikakos
Associate Professor
Icahn School of Medicine at Mount Sinai

Day One

Wednesday, February 23rd 2022

1:15 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

12:25 pm | Targeting Adaptive Resistance to RAS/MAPK-Directed Therapies

Frantz Jean- Francois
Team Lead
RAS initiative Frederick National Laboratory for Cancer Research

Day Two

Thursday, 24th February 2022

12:50 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

12:00 pm | PROTAC Mediated Degradation of KRAS

Michael Eck
Professor
Department of Biological Chemistry & Molecular Pharmacology Harvard Medical School

Day One

Wednesday, February 23rd 2022

5:40 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

4:25 pm | Structural Insights into Pharmacologic Targeting of the RAS/ RAF/MEK/ERK Pathway

Raghu Kalluri
Professor & Chair
Department of Cancer Biology The University of Texas MD Anderson Cancer Center

Day One

Wednesday, February 23rd 2022

10:40 am | Live Panel Q&A - Ask the Speakers Your Burning Questions

9:25 am | Targeting Oncogenic KRAS-G12D Mutation Employing Engineered Exosomes in Pancreatic Cancer

Siyuan Le
Senior Director of Biology
GenFleet Therapeutics

Day One

Wednesday, February 23rd 2022

5:40 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

5:15 pm | GFH925 (aka IBI351), A Novel Covalent Inhibitor for KRAS G12C

2:30 pm | Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers

Greg Jones
Principle Scientist, Team Leader
Pfizer

Day One

Wednesday, February 23rd 2022

2:30 pm | Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers

Day Two

Thursday, 24th February 2022

3:15 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

2:50 pm | Multi-Omics Data Integration Reveals Emerging Targets for RAS Mutant Cancers

Sreesha Srinivasa
Chief Development Officer
Oblique Therapeutics

Day Two

Thursday, 24th February 2022

12:50 pm | Live Panel Q&A - Ask the Speakers Your Burning Questions

12:25 pm | Targeting KRAS with Mutant Selective Monoclonal Antibodies

Mark Hallen
Chief Technology Officer
Ten63 Therapeutics

Rebika Shrestha
Scientist I, RAS Imaging and Assays, RAS Initiative
Frederick National Laboratory for Cancer Research

Erik Knelson
Principal Scientist, Early Oncology Development
Merck & Co

Trever Bivona
Professor, Hematology & Oncology
UCSF

Program Partner

Applied Biomath

Day One

Wednesday, February 23rd 2022

4:00 pm | Session Reserved for Program Partner

Expertise Partner

Promega

Day One

Wednesday, February 23rd 2022

10:40 am | Live Panel Q&A - Ask the Speakers Your Burning Questions

10:15 am | Session Reserved for Expertise Partner